PRESS RELEASE published on 08/28/2025 at 20:00, 1 year ago Inside Information / Other news releases GenSight Biologics postpones the release of its 2025 half-year financial results to September 29, 2025, after the market closes, to ensure highest audit standards. No material issues reported. Audit Committee and Board meetings rescheduled Financial Results Transparency Postponement GenSight Biologics Audit Procedures
BRIEF published on 07/17/2025 at 15:05, 1 year 2 months ago GenSight Biologics: Publication of an article on the predictions of LUMEVOQ® gene therapy Gene Therapy GenSight Biologics NOHL LUMEVOQ Visual Acuity
PRESS RELEASE published on 07/17/2025 at 15:00, 1 year 2 months ago Inside Information / Other news releases GenSight Biologics announces publication on predictors of final visual outcome in patients treated with LUMEVOQ® gene therapy. Study identifies key factors for improved visual acuity post-treatment Gene Therapy GenSight Biologics LUMEVOQ Visual Outcome Predictive Factors
BRIEF published on 07/17/2025 at 08:05, 1 year 2 months ago GenSight Biologics raises 500,000 euros to strengthen its development Funding GenSight Biologics Phase III Gene Therapies LUMEVOQ
BRIEF published on 07/03/2025 at 21:24, 1 year 2 months ago GenSight Biologics completes private placement of nearly €4 million Private Placement Common Shares Euronext Funding GenSight Biologics
PRESS RELEASE published on 07/03/2025 at 21:19, 1 year 2 months ago Inside Information / Operations of the issuer (acquisitions, sales...) GenSight Biologics closes EUR 3.9M private placement with issuance of ordinary shares, pre-funded warrants, investor warrants. Funds to repay convertible bonds. Maxim Group, LLC acted as placement agent Private Placement Ordinary Shares GenSight Biologics Maxim Group EUR 3.9M
BRIEF published on 07/01/2025 at 08:59, 1 year 2 months ago GenSight Biologics raises nearly €4 million in private placement Private Placement Investment GenSight Biologics Euronext Shares LUMEVOQ ®
PRESS RELEASE published on 07/01/2025 at 08:54, 1 year 2 months ago Inside Information / Operations of the issuer (acquisitions, sales...) GenSight Biologics successfully completes private placement of nearly EUR 4 million, attracting new international investors. Funds to advance gene therapies for retinal diseases and CNS disorders Private Placement GenSight Biologics Gene Therapies Retinal Diseases CNS Disorders
BRIEF published on 06/26/2025 at 07:35, 1 year 2 months ago GenSight Biologics: Advances in Manufacturing Partnership with Catalent Gene Therapy GenSight Biologics LUMEVOQ® NOHL Catalent
PRESS RELEASE published on 06/26/2025 at 07:30, 1 year 2 months ago Inside Information / Other news releases GenSight Biologics achieves significant milestone with new manufacturing partnership with Catalent, successfully transferring upstream phase of LUMEVOQ® manufacturing process Gene Therapy GenSight Biologics LUMEVOQ Catalent Manufacturing Partnership
Published on 09/17/2026 at 15:25, 23 minutes ago AIAI Holdings' Constellation Network Launches Dôr Patient Journey with Proactive MD(R), Expanding Transformational AI In Healthcare
Published on 09/17/2026 at 15:00, 48 minutes ago Norsemont Hits 41 Meters of 4.59 g/t Gold as Phase 3 Drilling Continues to Expand the Choquelimpie System
Published on 09/17/2026 at 15:00, 48 minutes ago ECC Ventures 4 Announces Termination of Agreement With Cambria Gold Mines Inc.
Published on 09/17/2026 at 14:50, 58 minutes ago Caldwell Strengthens Human Resources Practice with Addition of Ali Palmer as Partner
Published on 09/17/2026 at 14:47, 1 hour 1 minute ago Nextech3D.ai Announces CEO Evan Gappelberg Acquires 7.4 Million Shares
Published on 09/17/2026 at 15:30, 17 minutes ago Huawei Introduces OceanStor M900 Context Memory Storage to Accelerate AI Inference in Hyperscale Data Centers
Published on 09/16/2026 at 17:45, 22 hours 3 minutes ago Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 1 day 8 hours ago bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
Published on 09/15/2026 at 18:00, 1 day 21 hours ago Report on the Combined General Meeting of the 10th of September 2026
